SRRK Stock Scholar Rock Holding Corporation

$48.13
1d-4.45%5d+11.4%1m+11.93%ytd+9.26%
At close · Nov 20, 4:00 PM ET
After hours $48.13 +0% · Nov 20, 4:52 PM ET
52w low $38.6941% of range$61.76 52w high
Price

Today’s call · SRRK

All live ideas →

4 of 6 technical checks lean bullish

SRRK is turning down, momentum firm. $48.15 is the level overhead; $45.58 the first support below.

No open idea.Levels allow 127.5:1, but there is no confirmed entry yet — no breakout or pullback signal.
What would create one:
  • A close below $45.58 on rising volume (breakdown).
  • A bounce to $48.15 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · abovePrice vs 200-day · below50d vs 200d avg · belowMACD · bullishRSI momentum · 565-day tape · +11.4%
levelPrice is 0.04% from resistance $48.15 — watch for a break or rejection.
volumeVolume is expanding vs its 20-day average.
signalSRRK’s 50-day average is below the 200-day — long-term trend alignment is bearish.
All readings
TrendTurning down · above 50-day & below 200-day
MomentumRSI 55.8 · MACD bullish
Trend strengthADX 28.3 · strong trend
Location+6.3% vs 50-day MA
52-week range-20% from high · +27% from low
VolatilityATR 3.08 · ~6.4%/day
RSI 14
55.8
MACD
0.81
ADX 14
28.3
ATR 14
3.08
SMA 50
$45.28
SMA 200
$48.27

Levels that matter

$48.15swing zone · 4×+0.0%
$50round+3.9%
$51.41swing zone · 5×+6.8%
$45.58swing zone · 6×−5.3%
$45.28sma 50−5.9%
$45round−6.5%
Next earnings: Nov 10Date, time & past reactions →

Compare with…

Analyst overview · Nov 20

Scholar Rock Holding (SRRK) stock analysis, November 20, 2026: neutral stance, low conviction

Scholar Rock Holding (SRRK) closed at $48.13 on November 20, 2026, after a 4.4% drop that left it below its 40‑week average and under the swing‑zone resistance of $48.15. The stock has outperformed the S&P 500 over the past 50 days (+16.9%) and the healthcare sector ETF XLV (+5.5%), but the rally is not yet stretched and the weekly trend remains down. The balance of evidence points to a neutral outlook with low conviction for the next two to six weeks.

Why it matters

The recent 5‑day gain of 11.4% in SRRK came while the broader market fell 8.7% and the XLV sector slipped 6.3%, indicating that the move was largely stock‑specific. The price surged from the recent peak of $51.55 on November 9, shedding 6.6% to the current level, a pull‑back that erased much of the short‑term upside. The weekly trend remains down, as the price sits below its 40‑week average (48.27) and above the 10‑week average, a mixed signal that reflects lingering weakness despite the short‑term rally.

Analyst consensus is heavily bullish, with 16 analysts rating SRRK a strong buy and a mean price target of $70.06, which is 31.3% above the current price. However, the consensus does not alter the structural picture: the stock is still trading below the swing‑zone resistance where sellers have historically stepped in, and the long‑term trend is down. The valuation gap suggests optimism that is not yet supported by price action.

The debate among market participants centers on whether the recent outperformance versus the S&P 500 (+16.9% vs –8.7%) and XLV (+5.5% vs –6.3%) signals a durable shift or a temporary bounce. One side points to the strong relative performance and the 20.9% volume surge above the 20‑day average as evidence of buying interest. The other side highlights that the stock remains below the 50‑day SMA ($45.28) and the weekly trend is still negative, meaning the rally could falter if sellers reassert control.

Valuation remains a key tension. The mean target of $70.06 implies a 45% upside from today’s price, yet the downside risk to the stop at $48.92 (based on a quarter‑ATR addition to the swing‑zone low of $48.15) is modest. The price‑target spread therefore reflects a speculative premium that is not yet justified by the structural constraints.

What the evidence says

On the long‑term horizon, the thesis that SRRK is in a downtrend remains intact. The price is below its 40‑week average, the 200‑day SMA sits at $48.27, and the weekly trend is still negative. The stock’s RSI of 55.8 shows no extreme overbought or oversold condition, reinforcing a neutral bias.

For the next two to six weeks, the balance of evidence leans neutral with low conviction. The assessment lists a neutral stance, low conviction, and zero of four conviction points, driven by a rally that has not yet stretched, and the stock’s outperformance relative to the market and sector. The strongest case against a neutral view would be a break of the swing‑zone resistance at $48.15, which could trigger a sharper decline toward the $45.58 support. However, that scenario still leaves the reward‑to‑risk ratio low (0.1 to the first target), limiting its impact on the overall conviction.

Levels that matter

The structure currently holds above the swing‑zone resistance at $48.15, a level where sellers have previously stepped in on rallies. If price can stay above this point, the weekly downtrend would need to be broken above $51.41, also a swing‑zone level, to signal a potential trend reversal.

The breakout math is downside‑focused: a daily close below $45.58 would trigger the breakout level. The stop is set at $48.92, derived from $48.15 plus a quarter of the 14‑day ATR ($3.08). The first target is $45.28 (the 50‑day SMA) with a reward‑to‑risk of 0.1, and the second target is $42.58 (a deeper swing‑zone support) with a reward‑to‑risk of 0.9. The trade does not meet a 3‑to‑1 reward‑to‑risk; a price move to roughly $44.00 would be needed to approach that threshold.

What would change the picture

A weekly close above $51.41 would alter the current assessment, as that level is defined as the point where the weekly trend could end. Additionally, any unexpected earnings surprise—particularly a significant miss on revenue or guidance—could shift sentiment sharply, given the proximity of the earnings date on November 10.

What to watch

  • November 10 earnings release; the earnings per share figure and guidance revision will be the primary catalyst.
  • Sector developments in biotechnology, especially FDA approvals or setbacks, which tend to move SRRK ahead of its own news.
  • Analyst price targets: the consensus mean of $70.06 versus the current price reflects a 31% upside, a valuation gap to monitor.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.